Aug. 14, 2018
Dive
Brief:
- Activist
investor Carl Icahn has given up his fight to block Cigna's proposed $67
billion acquisition of Express Scripts. Icahn just last week warned
shareholders that the deal was among the "worst acquisitions in
corporate history" in an open letter.
- Cigna
responded to Icahn's criticism with a lengthy defense. In its
response, Cigna called Icahn's opposition "misguided and
short-sighted" and said it "demonstrates a clear lack of
understanding of the dynamics of the healthcare industry."
- Icahn reportedly abandoned his crusade after
shareholder advisory firms Institutional Shareholder Services Inc. and
Glass Lewis & Co. came out in support of the deal last week. Icahn
currently holds 0.56% of Cigna stake.
Dive
Insight:
Icahn's
last minute attempt to kill Cigna's acquisition of Express Scripts was "an
interesting wrinkle" in the deal's development, but "too little too
late," as predicted by Jefferies analysts.
While
the battle had reportedly been in the works for some time, similar attempts to
block deals have typically begun much earlier, such as Icahn's recent success
in nixing the Fujifilm and Xerox merger earlier this year.
Icahn
had raised three primary arguments against the acquisition in his open letter
to Cigna shareholders: The insurer is paying too much, it would be diving
directly into a risky sector embroiled in a political debate over drug pricing,
and would soon have to face off with Amazon, which is gearing up to take the
industry by storm.
Instead,
the activist investor proposed an alternative to the acquisition: That Cigna
engage in a multi-year partnership with Express Scripts (or another PBM) until
those regulatory and competitive concerns are ironed out.
While
less colorful than Icahn's open letter, Cigna's response addressed Icahn's
concerns directly.
"This
will position Cigna to deliver differentiated immediate and long-term value to
our shareholders in the form of strong EPS accretion, significant free cash
flow generation and exceptional financial flexibility in a highly dynamic
marketplace," the letter reads. "We believe that this delivers much
more substantial value than a quick financial engineering scheme for the
benefit of a singular, transitional investor, who claims to own only 0.56% of
Cigna’s outstanding common stock."
Cigna
shareholders are scheduled to vote on the Express Scripts acquisition Aug. 24.
No comments:
Post a Comment